TVM Life Science Ventures VII Invests in Ixchelsis to Take Premature …

TVM Life Science Ventures invested in Ixchelsis VII, a clinical-stage start-up that develops an antagonist of oxytocin receptors experimental IX-01 United Kingdom, for the potential treatment of premature ejaculation . IX-01 was

Read more…

This entry was posted in Premature Ejaculation and tagged , , , , , , , , , , , , , , , , , , , . Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *

Notify me of followup comments via e-mail. You can also subscribe without commenting.